Rimantadine: Difference between revisions
m (Protected "Rimantadine": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
m (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +)) |
||
| Line 21: | Line 21: | ||
{{SI}} | {{SI}} | ||
__NOTOC__ | __NOTOC__ | ||
'''For patient information, please click [[Rimantadine (patient information)|here]]''' | '''For patient information, please click [[Rimantadine (patient information)|here]]''' | ||
| Line 61: | Line 61: | ||
{{Influenza}} | {{Influenza}} | ||
[[es:Rimantadina]] | [[es:Rimantadina]] | ||
Revision as of 15:45, 20 August 2012
 | |
| Clinical data | |
|---|---|
| Pregnancy category |
|
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | well absorbed |
| Protein binding | 40% |
| Metabolism | Hepatic hydroxylation and glucuronidation |
| Elimination half-life | 25.4 ± 6.3 hours |
| Excretion | Renal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C12H21N |
| Molar mass | 179.302 g/mol |
|
WikiDoc Resources for Rimantadine |
|
Articles |
|---|
|
Most recent articles on Rimantadine Most cited articles on Rimantadine |
|
Media |
|
Powerpoint slides on Rimantadine |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Rimantadine at Clinical Trials.gov Clinical Trials on Rimantadine at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Rimantadine
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Rimantadine Discussion groups on Rimantadine Patient Handouts on Rimantadine Directions to Hospitals Treating Rimantadine Risk calculators and risk factors for Rimantadine
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Rimantadine |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
For patient information, please click here
Rimantadine (INN, sold under the trade name Flumadine) is an orally administered antiviral drug used to treat, and in rare cases prevent, Influenzavirus A infection. When taken within one to two days of developing symptoms, rimantadine can shorten the duration and moderate the severity of influenza. It is a derivate of adamantane, like a similar drug amantadine. It was approved by the Food and Drug Administration (FDA) in 1994.
Mechanics
Scientists do not understand why rimantadine works, but believe it inhibits influenza's viral replication, possibly by preventing the uncoating of the virus's protective shells, which are the envelope and capsid. Genetic studies suggest that the virus M2 protein, an ion channel specified by virion M2 gene, plays an important role in the susceptibility of influenza A virus to inhibition by rimantadine. Resistance to rimantadine can occur as a result of an amino acid substitutions at certain locations in the transmembrane region of M2. This prevents binding of the antiviral to the channel.
Drug interactions
Taking acetaminophen (Tylenol) or aspirin while taking rimantadine is known to reduce the body's uptake of rimantadine by approximately 12%.[1] Cimetidine also affects the body's uptake of rimantadine.
Adverse effects
Rimantadine can produce gastrointestinal and central nervous system adverse effects. Studies have shown it produces fewer side effects than other anti-viral influenza treatments. Approximately 6% of patients (compared to 6% of patients taking a placebo) reported side effects.[2] Common side effects include:
- nausea
- upset stomach
- nervousness
- tiredness
- lightheadedness
- trouble sleeping
- difficulty concentrating
Other Uses
Rimantadine, like its antiviral cousin amantadine, possesses some NMDA antagonistic properties and is used as an antiparkinsonic drug (ie, in the treatment of Parkinson's Disease). However, neither rimantadine nor amantadine are preferred agents for this therapy and are generally reserved for cases of the disease which are less responsive to front-line treatments.
External links
- U.S. FDA press release announcing rimantadine's approval
- U.S. Center for Drug Evaluation and Research rimantadine description
- U.S. NIH rimantadine description
- U.S. CDC flu anti-viral treatment information
|
Influenza Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Rimantadine On the Web |
|
American Roentgen Ray Society Images of Rimantadine |
- Pages with script errors
- Drugs with non-standard legal status
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Anti-influenza agents
- Influenza
- Infectious disease